Nashville, Tennessee
Colorectal cancer clinical trials in Nashville, TN
78 colorectal cancer studies are recruiting participants at sites in Nashville as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Nashville at a glance
- 78 studies are recruiting at a site in Nashville.
- By phase: Phase 1 (29), Phase 1/2 (23), Phase 2 (10), Phase 2/3 (2), Phase 3 (7), Phase 4 (1), No phase (1), Observational (5). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (66), university, hospital or other (9), government (3).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Nashville
Basic details from each study's public record (the 30 most recently updated of 78). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05863195 · updated
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study sites
- SCRI Oncology Partners · Tennessee Oncology, Pllc
- Registry record
- NCT06324357 · updated
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07213609 · updated
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Vividion Therapeutics, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06004245 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- Tennessee Oncology
- Registry record
- NCT06270706 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Sarah Cannon Research Institute Oncology Partners
- Registry record
- NCT07659795 · updated
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
- Registry record
- NCT04557449 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07020221 · updated
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07503808 · updated
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- SCRI Oncology Partners
- Registry record
- NCT04929223 · updated
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Riboscience, LLC.
- Study site
- SCRI Oncology LLC
- Registry record
- NCT06824064 · updated
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07549412 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05174169 · updated
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Jazz Pharmaceuticals
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06695845 · updated
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06760819 · updated
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Tennessee Oncology
- Registry record
- NCT07397338 · updated
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Vanderbilt Ingram Cancer Center
- Registry record
- NCT05379595 · updated
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05673148 · updated
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06662786 · updated
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study sites
- SCRI Oncology Partners · Tennessee Oncology · Vanderbilt University Medical Center
- Registry record
- NCT06750094 · updated
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kumquat Biosciences Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07542704 · updated
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Sarah Cannon Research Institute Oncology Partners
- Registry record
- NCT07584226 · updated
LYL273 for Patients With Relapsed or Refractory mCRC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- SCRI Oncology Partners and Tristar Centennial Hospital
- Registry record
- NCT05319314 · updated
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Vanderbilt Breast Center at One Hundred Oaks · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05803382 · updated
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- A2 Biotherapeutics Inc.
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT04981119 · updated
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06330064 · updated
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Alterome Therapeutics, Inc.
- Registry record
- NCT06835569 · updated
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07221357 · updated
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study sites
- SCRI Oncology Partners · Vanderbilt Medical Center
- Registry record
- NCT04657068 · updated
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT06239194 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Ask about studies near Nashville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections